Squamous cell carcinoma of the lung Diagnostic study of choice: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
(Created page with "__NOTOC__ {{Squamous cell carcinoma of the lung}} {{CMG}}; {{AE}} == Overview == == Diagnostic Study of Choice == ===== Template statements ===== === Study of choice: === *...")
 
 
(8 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Squamous cell carcinoma of the lung}}
{{Squamous cell carcinoma of the lung}}
{{CMG}}; {{AE}}
{{CMG}}; {{AE}} {{SH}}{{Trusha}}
== Overview ==
==Overview==
 
[[Computed tomography]] is the method of choice for the [[diagnosis]] of squamous cell carcinoma of the lung. On [[Computed tomography|CT]], findings of squamous cell carcinoma of the lung will depend on the location of the [[tumor]]. Characteristic findings include [[Ground glass opacification on CT|ground-glass opacity]], rounded or spiculated mass, local [[Lymph node|nodal]] involvement, intraluminar [[obstruction]], and lobar [[Collapsed lung|collapse]]. The [[Cancer staging|staging]] of lung cancer is based on the [[TNM|TNM classification]] of lung cancer. Lung [[cancer staging]] is an assessment of the degree of spread of cancer from its original source. It is an important factor affecting the [[prognosis]] and potential treatment of lung cancer. [[Non small cell lung cancer|Non-small cell lung carcinoma]] is staged from IA ("one A", best prognosis) to IVB ("four B", worst prognosis). Biopsy findings associated with squamous cell carcinoma of the lung include prominent [[nucleoli]], [[eosinophilic]] [[cytoplasm]], and [[intracellular]] bridges. Different sub-types of lung tissue [[biopsy]] for squamous cell carcinoma of the lung, include: [[needle biopsy]], open biopsy, and video-assisted thoracoscopic surgery.


== Diagnostic Study of Choice ==
== Diagnostic Study of Choice ==


===== Template statements =====
=== Study of Choice ===
 
*CT is the modality of choice for the evaluation of possible squamous cell carcinoma of the lung
*Certain morphological features can be suggestive of squamous cell carcinoma of the lung, such as:<ref name="pmid8190965">{{cite journal |vauthors=Rosado-de-Christenson ML, Templeton PA, Moran CA |title=Bronchogenic carcinoma: radiologic-pathologic correlation |journal=Radiographics |volume=14 |issue=2 |pages=429–46; quiz 447–8 |year=1994 |pmid=8190965 |doi=10.1148/radiographics.14.2.8190965 |url=}}</ref><ref name="pmid19234288">{{cite journal |vauthors=Parker MS, Chasen MH, Paul N |title=Radiologic signs in thoracic imaging: case-based review and self-assessment module |journal=AJR Am J Roentgenol |volume=192 |issue=3 Suppl |pages=S34–48 |year=2009 |pmid=19234288 |doi=10.2214/AJR.07.7081 |url=}}</ref>
 
:*[[Cavitation]], usually secondary to tumoral [[necrosis]]
:*Central [[Scar tissue|scar]]
:*Usually measure larger than 4 cm in diameter
*CT features involved in the diagnosis of squamous cell carcinoma of the lung include:
:*Staging of the disease
:*Dictation of the prognosis and treatment
 
*CT findings of squamous cell carcinoma of the lung, include:
 
:'''Central location'''
:*[[Intraluminal]] obstruction
:*Lung collapse and/or obstructive pneumonitis
:*[[Ground glass opacification on CT|Ground-glass opacity]]
:*Rounded or spiculated mass
:*Local nodal involvement
:*Intraluminar obstruction
:*Segmental or lobar [[Collapsed lung|lung collapse]]
 
:'''Peripheral location'''
:*Solid nodule/mass with or without an irregular border
:*Irregular margins
:*[[Desmoplasia|Desmoplastic]] reaction or infiltrative growth
:*Similar to central [[lung cancer]], peripheral squamous cell carcinoma of the lung can also result in obstructive changes such as a [[mucocele]].
 
*On CT, signs of squamous cell carcinoma of the lung, may include:<ref name="pmid7208937">{{cite journal |vauthors=Kundel HL |title=Predictive value and threshold detectability of lung tumors |journal=Radiology |volume=139 |issue=1 |pages=25–9 |year=1981 |pmid=7208937 |doi=10.1148/radiology.139.1.7208937 |url=}}</ref><ref name="pmid19234288">{{cite journal |vauthors=Parker MS, Chasen MH, Paul N |title=Radiologic signs in thoracic imaging: case-based review and self-assessment module |journal=AJR Am J Roentgenol |volume=192 |issue=3 Suppl |pages=S34–48 |year=2009 |pmid=19234288 |doi=10.2214/AJR.07.7081 |url=}}</ref>
 
:* '''Finger in glove sign''': the bronchus distal to the obstruction is dilated
:* '''Crazy-paving sign''':  appearance of ground-glass opacity with superimposed interlobular septal thickening and intralobular reticular thickening
 
==Gallery==
 
<div align="left">
<gallery heights="175" widths="175">
Image:Bronchogenic-carcinoma-with-upper-lobe-collapse.jpg|'''Bronchogenic lung carcincoma''': upper lobe collapse via, radiopedia.org Case courtesy of Dr Ahmed Abdrabou, <ref> href="https://radiopaedia.org/">Radiopaedia.org</a>. From the case <a href="https://radiopaedia.org/cases/29297">rID: 29297</ref>
Image:Bronchogenic-carcinoma-with-lymphangitic-spread.jpg|'''Bronchogenic lung carcincoma''': upper lobe with lymphangitic spread via, radiopedia.org Case courtesy of Dr Ahmed Abdrabou, <ref> href="https://radiopaedia.org/">Radiopaedia.org</a>. From the case <a href="https://radiopaedia.org/cases/29002">rID: 29002</ref>
Image:Lung-squamous-cell-carcinoma.jpg|'''Squamous cell lung carcinoma''': Peripheral squamous cell lung carcinoma may be seen as a solid nodule/mass with or without an irregular border. The irregular margin can be attributed to a desmoplastic reaction or infiltrative growth via, radiopedia.org Case courtesy of Dr Bruno Di Muzio, <ref> href="https://radiopaedia.org/">Radiopaedia.org</a>. From the case <a href="https://radiopaedia.org/cases/27915">rID: 27915</ref>
</gallery>
</div>


=== Study of choice: ===
== Staging ==
* [Name of the investigation] is the gold standard test for the diagnosis of [disease name].
The following is 2017 TNM classification of lung cancer.<ref>{{cite book | last =Mountain | first =CF | authorlink = | coauthors =Libshitz HI, Hermes KE | title =A Handbook for Staging, Imaging, and Lymph Node Classification | publisher =Charles P Young Company | date =2003 | url =http://www.ctsnet.org/book/mountain/index.html | accessdate =2007-09-01 }}</ref><ref name="Collins">{{cite journal | last = Collins | first = LG | coauthors = Haines C, Perkel R, Enck RE | title = Lung cancer: diagnosis and management | journal = American Family Physician | volume = 75 | issue = 1 | pages = 56–63 | publisher = American Academy of Family Physicians | date = Jan 2007 | url= http://www.aafp.org/afp/20070101/56.html | pmid =17225705 | accessdate =2007-08-10 }}</ref><ref name="HarmsKriegsmann2017">{{cite journal|last1=Harms|first1=A.|last2=Kriegsmann|first2=M.|last3=Fink|first3=L.|last4=Länger|first4=F.|last5=Warth|first5=A.|title=Die neue TNM-Klassifikation für Lungentumoren|journal=Der Pathologe|volume=38|issue=1|year=2017|pages=11–20|issn=0172-8113|doi=10.1007/s00292-017-0268-y}}</ref>
* The following result of [gold standard test] is confirmatory of [disease name]:
** Result 1
** Result 2
* The [name of the investigation] should be performed when:
** The patient presented with symptoms/signs 1. 2, 3.
** A positive [test] is detected in the patient.
* [Name of the investigation] is the gold standard test for the diagnosis of [disease name].
* The diagnostic study of choice for [disease name] is [name of the investigation].
* There is no single diagnostic study of choice for the diagnosis of [disease name].  
* There is no single diagnostic study of choice for the diagnosis of [disease name], but [disease name] can be diagnosed based on [name of the investigation 1] and [name of the investigation 2].
* [Disease name] is mainly diagnosed based on clinical presentation.
* Investigations:
** Among patients who present with clinical signs of [disease name], the [investigation name] is the most specific test for the diagnosis.
** Among patients who present with clinical signs of [disease name], the [investigation name] is the most sensitive test for diagnosis.
** Among patients who present with clinical signs of [disease name], the [investigation name] is the most efficient test for diagnosis.


==== The comparison table for diagnostic studies of choice for [disease name] ====
===T: Primary Tumor===
{|
{|
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | Test
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Sensitivity
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Specificity
|-
|-
! style="background: #696969; color: #FFFFFF; text-align: center;" |Test 1
| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" |'''T'''|| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align="center" |'''Description'''
| style="background: #DCDCDC; padding: 5px; text-align: center;" |✔
| style="background: #DCDCDC; padding: 5px; text-align: center;" |...%
|-
|-
! style="background: #696969; color: #FFFFFF; text-align: center;" |Test 2
! style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |TX
| style="background: #DCDCDC; padding: 5px; text-align: center;" |...%
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |Primary tumor cannot be assessed.<br> OR <br>Tumor is demonstrated by the presence of malignant cells in bronchial washings or [[sputum]], but is not visualized by imaging or [[bronchoscopy]].
| style="background: #DCDCDC; padding: 5px; text-align: center;" |✔
|-
! style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" | T0
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |There is no evidence of primary tumor.
|-
! style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |Tis
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |Carcinoma in situ
|-
! style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T1
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |The tumor has the following characteristics:
 
* T1a: tumor ≤1 cm in the largest diameter.
 
* T1b: tumor> 1 cm, but ≤2 cm in the largest diameter.
* T1c: tumor> 2 cm, but ≤3 cm in the largest diameter.<br> AND <br>The tumor is surrounded by lung or [[visceral pleura]]<br> AND <br>The tumor does not extend to the main bronchus as demonstrated by the absence of bronchoscopic evidence of invasion more proximal than the lobar bronchus.
|-
! style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T2
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |The tumor has the following characteristics:
 
* T2a: tumor > 3 cm, but ≤ 4 cm in the largest diameter.
* T2b: Tumor > 4 cm, but ≤ 5 cm in the largest diameter.<br>The tumor involves the main bronchus, 2 cm or more distal to the [[carina]]. <br> OR <br>The tumor invades the [[visceral pleura]]. <br> OR <br>There is evidence of [[atelectasis]] or obstructive [[pneumonitis]] that extends to the hilar region without the involvement of the entire lung.
|-
! style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T3
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |Tumor > 5 cm, but ≤ 7 cm in size.
AND
 
It directly invades any of the following: [[chest wall]] (including superior sulcus tumors), [[diaphragm]], mediastinal pleura, parietal [[pericardium]].<br> OR <br>The tumor is localized in the main bronchus at a distance less than 2 cm distal to the [[carina]] but without the involvement of the [[carina]].<br> OR <br>There is evidence of associated [[atelectasis]] or obstructive [[pneumonitis]] of the entire lung.
|-
! style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T4
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |Tumor > 7 cm in size.
The tumor invades any of the following: [[mediastinum]], [[heart]], great vessels, [[trachea]], [[esophagus]], [[vertebral body]], [[carina]]<br> OR <br>There is/are separate tumor nodule(s) in the same lobe. <br> OR
The tumor is associated with malignant [[pleural effusion]].
|}
|}
<small> ✔= The best test based on the feature </small>


===== Diagnostic results =====
===N:Regional Lymph Nodes===
The following result of [investigation name] is confirmatory of [disease name]:
{| style="cellpadding=0; cellspacing= 0; width: 600px;"
* Result 1
|-
* Result 2
| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" |'''T'''|| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align="center" |'''Description'''
|-
! style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |NX
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |The regional [[lymph node]]s cannot be assessed.
|-
! style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N0
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |There is no evidence of regional lymph node metastasis.
|-
! style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N1
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |[[Metastasis]] in [[Anatomical terms of location|ipsilateral]] peribronchial and/or [[Anatomical terms of location|ipsilateral]] [[Hilar lymphadenopathy|hilum]] or intrapulmonary [[Lymph node|lymph nodes]]
N1a: A [[lymph node]] invasion.
 
N1b: > 1 [[lymph node]] affected.
|-
! style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N2
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |There is [[metastasis]] in ipsilateral [[Mediastinum|mediastinal]] and/or subcarinal [[Lymph node|lymph node(s).]]
N2a1: One lymph node infested without lymph node involvement of an N1-defined lymph node station.
 
N2a2: One lymph node infested with a lymph node of an N1-defined lymph node station
 
N2b: > 1 lymph node affected
|-
! style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N3
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |There is [[metastasis]] in [[Anatomical terms of location|contralateral]] [[Mediastinum|mediastinal]], contralateral [[Hilum|hilar]], [[Anatomical terms of location|ipsilateral]] or [[Anatomical terms of location|contralateral]] scalene, or supraclavicular [[Lymph node|lymph node(s).]]
|}
 
===M: Distant Metastasis===
{| style="cellpadding=0; cellspacing= 0; width: 600px;"
|-
| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 10%" align="center" |'''T'''|| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align="center" |'''Description'''
|-
! style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |MX
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |Distant metastasis cannot be assessed.
|-
! style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |There is no evidence of distant [[metastasis]].
|-
! style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M1
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |There is evidence of [[distant]] metastasis which includes the presence of separate tumor nodule(s) in a different lobe (ipsilateral or contralateral).
M1a: Tumor foci separated from the primary tumor in a contralateral lung lobe; Tumor with pleural metastases or malignant pleural or pericardial effusion
 
M1b: Simple metastases in an organ
 
M1c: Multiple metastases in one organ or one or more metastases in more than one organ
 
|}<br />
===Classification of Lung Cancer by Staging===
{| style="cellpadding=0; cellspacing= 0; width: 600px;"
|-
| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align="center" |'''Stage'''|| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align="center" |'''T'''|| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align="center" |'''N'''|| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF" align="center" |'''M'''
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |'''Occult carcinoma''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |TX|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N0|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |'''Stage 0''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |Tis || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" | N0 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |'''Stage IA1''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T1(mi)/T1a || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N0 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |'''Stage IA2''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T1b || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N0 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" | M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" | '''Stage IA3'''|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T1c || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N0 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" | M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |'''Stage IB''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T2a || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N0 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" | M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |'''Stage IIA''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T2b || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N0 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| rowspan="5" style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |'''Stage IIB''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T1a || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N1 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" | M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T1c || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N1 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T2a || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N1 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T2b || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N1 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N0 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| rowspan="13" style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |'''Stage IIIA''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T1a
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N2 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T1b || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N2 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T1c || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N2 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T2a || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N2 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T2b || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N2 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T1a || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N2 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T1b || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N2 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T1c || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N2 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T2a || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N2 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T2b || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N2 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N1 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T4 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N0 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T4|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N1 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| rowspan="12" style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |'''Stage IIIB''' || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T1a|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T1b || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T1c || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T2a || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T2b || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T1a || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T1b || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T1c || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T2a || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T2b || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N2 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T4 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N2 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| rowspan="2"  style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |'''Stage IIIC'''|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |T4 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |N3 || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M0
|-
| rowspan="2" style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |'''Stage IVA'''|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |Any T || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |Any N || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M1a
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |Any T || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |Any N || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M1b
|-
| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |'''Stage IVB'''|| style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |Any T || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |Any N || style="font-size: 100; padding: 0 5px; background: #B8B8B8" align="left" |M1c
|}<br />
===Biopsy===
 
*Common types of lung tissue biopsy, include:<ref name="pmid12820712">{{cite journal |vauthors=Yung RC |title=Tissue diagnosis of suspected lung cancer: selecting between bronchoscopy, transthoracic needle aspiration, and resectional biopsy |journal=Respir Care Clin N Am |volume=9 |issue=1 |pages=51–76 |year=2003 |pmid=12820712 |doi= |url=}}</ref>


===== Sequence of Diagnostic Studies =====
:*[[Needle biopsy]]
The [name of investigation] should be performed when:
:*Open biopsy
* The patient presented with symptoms/signs 1, 2, and 3 as the first step of diagnosis.
:*Video-assisted thoracoscopic surgery (VATS)
* A positive [test] is detected in the patient, to confirm the diagnosis.
*Indications for lung tissue biopsy in squamous cell carcinoma of the lung, include:<ref name="NSCLS2">Squamous cell carcinoma of the lung. Libre Pathology http://librepathology.org/wiki/Squamous_cell_carcinoma_of_the_lung Accessed on March 1, 2016</ref>
:*Determination of tumor histologic subtype
:*Characterization of [[genetic mutations]]
:*Determination of intra or extra-thoracic metastatic disease


=== Diagnostic Criteria ===
*The table below summarizes the squamous cell carcinoma of the lung biopsy findings.<ref name="NSCLS2">Squamous cell carcinoma of the lung. Libre Pathology http://librepathology.org/wiki/Squamous_cell_carcinoma_of_the_lung Accessed on March 1, 2016</ref>
* Here you should describe the details of the diagnostic criteria.
*Always mention the name of the criteria/definition you are about to list (e.g. modified Duke criteria for the diagnosis of endocarditis / 3rd universal definition of MI) and cite the primary source of where this criteria/definition is found.
*Although not necessary, it is recommended that you include the criteria in a table. Make sure you always cite the source of the content and whether the table has been adapted from another source.
*Be very clear as to the number of criteria (or threshold) that needs to be met out of the total number of criteria.
*Distinguish criteria based on their nature (e.g. clinical criteria / pathological criteria/ imaging criteria) before discussing them in details.
*To view an example (endocarditis diagnostic criteria), click [[Endocarditis diagnosis|here]]
*If relevant, add additional information that might help the reader distinguish various criteria or the evolution of criteria (e.g. original criteria vs. modified criteria).
*You may also add information about the sensitivity and specificity of the criteria, the pre-test probability, and other figures that may help the reader understand how valuable the criteria are clinically.
* [Disease name] is mainly diagnosed based on clinical presentation. There are no established criteria for the diagnosis of [disease name].
* There is no single diagnostic study of choice for [disease name], though [disease name] may be diagnosed based on [name of criteria] established by [...].


* The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met: [criterion 1], [criterion 2], [criterion 3], and [criterion 4].
{| style="border: 0px; font-size: 90%; margin: 3px; width: 400px" align="center"
* The diagnosis of [disease name] is based on the [criteria name] criteria, which includes [criterion 1], [criterion 2], and [criterion 3].
| valign="top" |
|+
|-
! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF|Type of tumor }}
! style="background: #4479BA; width: 250px;" | {{fontcolor|#FFF|Biopsy findings}}
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" | [[Squamous-cell cancer|Squamous cell lung carcinoma]]
| style="padding: 5px 5px; background: #F5F5F5;" |
*Central nucleus
*Dense appearing [[cytoplasm]], usually [[eosinophilic]]
*Small [[nucleolus]]
*Intracellular bridges - classic
|-
|}


* [Disease name] may be diagnosed at any time if one or more of the following criteria are met:
==References==
** Criteria 1
{{reflist|2}}
** Criteria 2
** Criteria 3


IF there are clear, established diagnostic criteria:
{{WikiDoc Help Menu}}
*The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met: [criterion 1], [criterion 2], [criterion 3], and [criterion 4].
{{WikiDoc Sources}}
*The diagnosis of [disease name] is based on the [criteria name] criteria, which include [criterion 1], [criterion 2], and [criterion 3].
 
*The diagnosis of [disease name] is based on the [definition name] definition, which includes [criterion 1], [criterion 2], and [criterion 3].
[[Category:Disease]]
IF there are no established diagnostic criteria: 
[[Category:Types of cancer]]
*There are no established criteria for the diagnosis of [disease name].
[[Category:Pulmonology]]
[[Category:Lung cancer]]
[[Category:Oncology]]
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Pulmonology]]
[[Category:Surgery]]




==References==
==References==
{{Reflist|2}}
{{reflist|2}}
{{WH}}
 
{{WS}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
 
[[Category:Disease]]
[[Category:Types of cancer]]
[[Category:Pulmonology]]
[[Category:Lung cancer]]
[[Category:Oncology]]
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Pulmonology]]
[[Category:Surgery]]

Latest revision as of 19:52, 18 October 2019

Squamous Cell Carcinoma of the Lung Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Squamous Cell Carcinoma of the Lung from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic study of choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Squamous cell carcinoma of the lung Diagnostic study of choice On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Squamous cell carcinoma of the lung Diagnostic study of choice

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Squamous cell carcinoma of the lung Diagnostic study of choice

CDC on Squamous cell carcinoma of the lung Diagnostic study of choice

Squamous cell carcinoma of the lung Diagnostic study of choice in the news

Blogs on Squamous cell carcinoma of the lung Diagnostic study of choice

Directions to Hospitals Treating Squamous cell carcinoma of the lung

Risk calculators and risk factors for Squamous cell carcinoma of the lung Diagnostic study of choice

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dildar Hussain, MBBS [2] Trusha Tank, M.D.[3]

Overview

Computed tomography is the method of choice for the diagnosis of squamous cell carcinoma of the lung. On CT, findings of squamous cell carcinoma of the lung will depend on the location of the tumor. Characteristic findings include ground-glass opacity, rounded or spiculated mass, local nodal involvement, intraluminar obstruction, and lobar collapse. The staging of lung cancer is based on the TNM classification of lung cancer. Lung cancer staging is an assessment of the degree of spread of cancer from its original source. It is an important factor affecting the prognosis and potential treatment of lung cancer. Non-small cell lung carcinoma is staged from IA ("one A", best prognosis) to IVB ("four B", worst prognosis). Biopsy findings associated with squamous cell carcinoma of the lung include prominent nucleoli, eosinophilic cytoplasm, and intracellular bridges. Different sub-types of lung tissue biopsy for squamous cell carcinoma of the lung, include: needle biopsy, open biopsy, and video-assisted thoracoscopic surgery.

Diagnostic Study of Choice

Study of Choice

  • CT is the modality of choice for the evaluation of possible squamous cell carcinoma of the lung
  • Certain morphological features can be suggestive of squamous cell carcinoma of the lung, such as:[1][2]
  • CT features involved in the diagnosis of squamous cell carcinoma of the lung include:
  • Staging of the disease
  • Dictation of the prognosis and treatment
  • CT findings of squamous cell carcinoma of the lung, include:
Central location
Peripheral location
  • Solid nodule/mass with or without an irregular border
  • Irregular margins
  • Desmoplastic reaction or infiltrative growth
  • Similar to central lung cancer, peripheral squamous cell carcinoma of the lung can also result in obstructive changes such as a mucocele.
  • On CT, signs of squamous cell carcinoma of the lung, may include:[3][2]
  • Finger in glove sign: the bronchus distal to the obstruction is dilated
  • Crazy-paving sign: appearance of ground-glass opacity with superimposed interlobular septal thickening and intralobular reticular thickening

Gallery

  • Bronchogenic lung carcincoma: upper lobe collapse via, radiopedia.org Case courtesy of Dr Ahmed Abdrabou, [4]

    Bronchogenic lung carcincoma: upper lobe collapse via, radiopedia.org Case courtesy of Dr Ahmed Abdrabou, [4]

  • Bronchogenic lung carcincoma: upper lobe with lymphangitic spread via, radiopedia.org Case courtesy of Dr Ahmed Abdrabou, [5]

    Bronchogenic lung carcincoma: upper lobe with lymphangitic spread via, radiopedia.org Case courtesy of Dr Ahmed Abdrabou, [5]

  • Squamous cell lung carcinoma: Peripheral squamous cell lung carcinoma may be seen as a solid nodule/mass with or without an irregular border. The irregular margin can be attributed to a desmoplastic reaction or infiltrative growth via, radiopedia.org Case courtesy of Dr Bruno Di Muzio, [6]

    Squamous cell lung carcinoma: Peripheral squamous cell lung carcinoma may be seen as a solid nodule/mass with or without an irregular border. The irregular margin can be attributed to a desmoplastic reaction or infiltrative growth via, radiopedia.org Case courtesy of Dr Bruno Di Muzio, [6]

Staging

The following is 2017 TNM classification of lung cancer.[7][8][9]

T: Primary Tumor

T Description
TX Primary tumor cannot be assessed.
OR
Tumor is demonstrated by the presence of malignant cells in bronchial washings or sputum, but is not visualized by imaging or bronchoscopy.
T0 There is no evidence of primary tumor.
Tis Carcinoma in situ
T1 The tumor has the following characteristics:
  • T1a: tumor ≤1 cm in the largest diameter.
  • T1b: tumor> 1 cm, but ≤2 cm in the largest diameter.
  • T1c: tumor> 2 cm, but ≤3 cm in the largest diameter.
    AND
    The tumor is surrounded by lung or visceral pleura
    AND
    The tumor does not extend to the main bronchus as demonstrated by the absence of bronchoscopic evidence of invasion more proximal than the lobar bronchus.
T2 The tumor has the following characteristics:
  • T2a: tumor > 3 cm, but ≤ 4 cm in the largest diameter.
  • T2b: Tumor > 4 cm, but ≤ 5 cm in the largest diameter.
    The tumor involves the main bronchus, 2 cm or more distal to the carina.
    OR
    The tumor invades the visceral pleura.
    OR
    There is evidence of atelectasis or obstructive pneumonitis that extends to the hilar region without the involvement of the entire lung.
T3 Tumor > 5 cm, but ≤ 7 cm in size.

AND

It directly invades any of the following: chest wall (including superior sulcus tumors), diaphragm, mediastinal pleura, parietal pericardium.
OR
The tumor is localized in the main bronchus at a distance less than 2 cm distal to the carina but without the involvement of the carina.
OR
There is evidence of associated atelectasis or obstructive pneumonitis of the entire lung.

T4 Tumor > 7 cm in size.

The tumor invades any of the following: mediastinum, heart, great vessels, trachea, esophagus, vertebral body, carina
OR
There is/are separate tumor nodule(s) in the same lobe.
OR The tumor is associated with malignant pleural effusion.

N:Regional Lymph Nodes

T Description
NX The regional lymph nodes cannot be assessed.
N0 There is no evidence of regional lymph node metastasis.
N1 Metastasis in ipsilateral peribronchial and/or ipsilateral hilum or intrapulmonary lymph nodes

N1a: A lymph node invasion.

N1b: > 1 lymph node affected.

N2 There is metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s).

N2a1: One lymph node infested without lymph node involvement of an N1-defined lymph node station.

N2a2: One lymph node infested with a lymph node of an N1-defined lymph node station

N2b: > 1 lymph node affected

N3 There is metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s).

M: Distant Metastasis

T Description
MX Distant metastasis cannot be assessed.
M0 There is no evidence of distant metastasis.
M1 There is evidence of distant metastasis which includes the presence of separate tumor nodule(s) in a different lobe (ipsilateral or contralateral).

M1a: Tumor foci separated from the primary tumor in a contralateral lung lobe; Tumor with pleural metastases or malignant pleural or pericardial effusion

M1b: Simple metastases in an organ

M1c: Multiple metastases in one organ or one or more metastases in more than one organ


Classification of Lung Cancer by Staging

Stage T N M
Occult carcinoma TX N0 M0
Stage 0 Tis N0 M0
Stage IA1 T1(mi)/T1a N0 M0
Stage IA2 T1b N0 M0
Stage IA3 T1c N0 M0
Stage IB T2a N0 M0
Stage IIA T2b N0 M0
Stage IIB T1a N1 M0
T1c N1 M0
T2a N1 M0
T2b N1 M0
T3 N0 M0
Stage IIIA T1a N2 M0
T1b N2 M0
T1c N2 M0
T2a N2 M0
T2b N2 M0
T1a N2 M0
T1b N2 M0
T1c N2 M0
T2a N2 M0
T2b N2 M0
T3 N1 M0
T4 N0 M0
T4 N1 M0
Stage IIIB T1a N3 M0
T1b N3 M0
T1c N3 M0
T2a N3 M0
T2b N3 M0
T1a N3 M0
T1b N3 M0
T1c N3 M0
T2a N3 M0
T2b N3 M0
T3 N2 M0
T4 N2 M0
Stage IIIC T3 N3 M0
T4 N3 M0
Stage IVA Any T Any N M1a
Any T Any N M1b
Stage IVB Any T Any N M1c


Biopsy

  • Common types of lung tissue biopsy, include:[10]
  • Needle biopsy
  • Open biopsy
  • Video-assisted thoracoscopic surgery (VATS)
  • Indications for lung tissue biopsy in squamous cell carcinoma of the lung, include:[11]
  • Determination of tumor histologic subtype
  • Characterization of genetic mutations
  • Determination of intra or extra-thoracic metastatic disease
  • The table below summarizes the squamous cell carcinoma of the lung biopsy findings.[11]
Type of tumor Biopsy findings
Squamous cell lung carcinoma

References

  1. ↑ Rosado-de-Christenson ML, Templeton PA, Moran CA (1994). "Bronchogenic carcinoma: radiologic-pathologic correlation". Radiographics. 14 (2): 429–46, quiz 447–8. doi:10.1148/radiographics.14.2.8190965. PMID 8190965.
  2. ↑ 2.0 2.1 Parker MS, Chasen MH, Paul N (2009). "Radiologic signs in thoracic imaging: case-based review and self-assessment module". AJR Am J Roentgenol. 192 (3 Suppl): S34–48. doi:10.2214/AJR.07.7081. PMID 19234288.
  3. ↑ Kundel HL (1981). "Predictive value and threshold detectability of lung tumors". Radiology. 139 (1): 25–9. doi:10.1148/radiology.139.1.7208937. PMID 7208937.
  4. ↑ href="https://radiopaedia.org/">Radiopaedia.org</a>. From the case <a href="https://radiopaedia.org/cases/29297">rID: 29297
  5. ↑ href="https://radiopaedia.org/">Radiopaedia.org</a>. From the case <a href="https://radiopaedia.org/cases/29002">rID: 29002
  6. ↑ href="https://radiopaedia.org/">Radiopaedia.org</a>. From the case <a href="https://radiopaedia.org/cases/27915">rID: 27915
  7. ↑ Mountain, CF (2003). A Handbook for Staging, Imaging, and Lymph Node Classification. Charles P Young Company. Retrieved 2007-09-01. Unknown parameter |coauthors= ignored (help)
  8. ↑ Collins, LG (Jan 2007). "Lung cancer: diagnosis and management". American Family Physician. American Academy of Family Physicians. 75 (1): 56–63. PMID 17225705. Retrieved 2007-08-10. Unknown parameter |coauthors= ignored (help)
  9. ↑ Harms, A.; Kriegsmann, M.; Fink, L.; Länger, F.; Warth, A. (2017). "Die neue TNM-Klassifikation für Lungentumoren". Der Pathologe. 38 (1): 11–20. doi:10.1007/s00292-017-0268-y. ISSN 0172-8113.
  10. ↑ Yung RC (2003). "Tissue diagnosis of suspected lung cancer: selecting between bronchoscopy, transthoracic needle aspiration, and resectional biopsy". Respir Care Clin N Am. 9 (1): 51–76. PMID 12820712.
  11. ↑ 11.0 11.1 Squamous cell carcinoma of the lung. Libre Pathology http://librepathology.org/wiki/Squamous_cell_carcinoma_of_the_lung Accessed on March 1, 2016


Template:WikiDoc Sources


References


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Squamous_cell_carcinoma_of_the_lung_Diagnostic_study_of_choice&oldid=1585123"